- Home
- MQ vs BLTE Comparison
MQ vs BLTE Comparison
Compare MQ & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQ
- BLTE
- Stock Information
- Founded
- MQ 2010
- BLTE 2018
- Country
- MQ United States
- BLTE United States
- Employees
- MQ N/A
- BLTE N/A
- Industry
- MQ Computer Software: Prepackaged Software
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- MQ Technology
- BLTE Health Care
- Exchange
- MQ Nasdaq
- BLTE Nasdaq
- Market Cap
- MQ 1.9B
- BLTE 2.1B
- IPO Year
- MQ 2021
- BLTE 2022
- Fundamental
- Price
- MQ $5.83
- BLTE $63.80
- Analyst Decision
- MQ Hold
- BLTE Strong Buy
- Analyst Count
- MQ 13
- BLTE 4
- Target Price
- MQ $5.15
- BLTE $96.67
- AVG Volume (30 Days)
- MQ 5.9M
- BLTE 71.5K
- Earning Date
- MQ 08-06-2025
- BLTE 08-08-2025
- Dividend Yield
- MQ N/A
- BLTE N/A
- EPS Growth
- MQ N/A
- BLTE N/A
- EPS
- MQ 0.11
- BLTE N/A
- Revenue
- MQ $528,100,000.00
- BLTE N/A
- Revenue This Year
- MQ $19.30
- BLTE N/A
- Revenue Next Year
- MQ $21.97
- BLTE N/A
- P/E Ratio
- MQ $54.51
- BLTE N/A
- Revenue Growth
- MQ N/A
- BLTE N/A
- 52 Week Low
- MQ $3.37
- BLTE $43.70
- 52 Week High
- MQ $6.01
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- MQ 58.45
- BLTE 60.46
- Support Level
- MQ $5.70
- BLTE $60.60
- Resistance Level
- MQ $6.01
- BLTE $64.20
- Average True Range (ATR)
- MQ 0.13
- BLTE 2.40
- MACD
- MQ -0.04
- BLTE 0.74
- Stochastic Oscillator
- MQ 42.86
- BLTE 99.67
About MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.